Mary Anne Dooley, MD
Rheumatology · Clayton, NCNPI 1376616185
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,200 of the $80,496 with a category attached, or 76.0%. GSK accounts for 97.5% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $42,884 and has fallen 98.6% since, to $603 in 2025. Among rheumatology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $452.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$79K
- UCB, Inc.$306
- Amgen$304
- Pfizer$184
- Boston Scientific$158
- AbbVie$136
- plus $892 from 16 others
Across 1 payment — averaging $2721.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3K
What the payments were for
- Consulting fees$5,4557%
- Speaking & faculty fees$61,20076%
- Travel & lodging$10,17113%
- Food & beverage$3,6505%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 78 | $78,516 |
| UCB, Inc. | 14 | $306 |
| Amgen(2 entities) | 16 | $304 |
| Pfizer | 11 | $184 |
| Boston Scientific | 3 | $158 |
| AbbVie | 7 | $136 |
| Novo Nordisk | 7 | $129 |
| AstraZeneca(2 entities) | 7 | $119 |
| Johnson & Johnson | 6 | $115 |
| Boehringer Ingelheim | 4 | $82 |
| Lilly USA, LLC | 5 | $79 |
| Novartis | 3 | $61 |
| Exact Sciences | 3 | $54 |
| Aurinia Pharma U.S., Inc. | 3 | $50 |
| Argenx US, Inc. | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Genentech USA, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $17 |
| Sandoz | 1 | $15 |
| CSL Behring | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$77,005
- WaveWriter Alpha Prime 16$115
How this compares
$80,496 in reported general payments places this provider in the 90th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 51 | $353,156 |
| Enbrel SureclickEtanercept | 46 | $345,731 |
| Cimzia (2 Pack)Certolizumab Pegol | 18 | $143,877 |
| XeljanzTofacitinib Citrate | 18 | $120,738 |
| BenlystaBelimumab | 22 | $102,177 |
| OtezlaApremilast | 21 | $99,139 |
| EnbrelEtanercept | 11 | $82,363 |
| Cosentyx Unoready PenSecukinumab | 11 | $81,914 |
| Hydroxychloroquine Sulfate | 296 | $11,151 |
| MethotrexateMethotrexate Sodium | 270 | $5,624 |
| Mycophenolate Mofetil | 48 | $4,644 |
| Diclofenac Sodium | 68 | $3,621 |
| Prednisone | 407 | $3,590 |
| Leflunomide | 61 | $2,994 |
| Cyclobenzaprine Hcl | 104 | $712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel | $304 | $181,50132 claims |
| UCB, Inc.Cimzia (2 Pack) | $306 | $143,87718 claims |
| PfizerXeljanz | $184 | $120,73818 claims |
| GSKBenlysta | $78,516 | $102,17722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 rheumatology providers in North Carolina.
Other rheumatology in Clayton
- Gordon LamCharlotte$2.7M
- Ralph SnydermanDurham$1.3M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
- Joseph ShanahanDurham$407K
- Jill ZouzoulasCharlotte$377K
- Jill VargoAsheville$245K
- Robert HolmesPollocksville$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.